Clinical TrialMay 21, 2026, 11:06 AM
Tiziana Life Sciences Completes Enrollment in Phase 2a MS Trial
AI Summary
Tiziana Life Sciences Ltd announced the completion of patient enrollment in its Phase 2a clinical trial evaluating intranasal foralumab for non-active Secondary Progressive Multiple Sclerosis (na-SPMS). This randomized, double-blind, placebo-controlled study, known as INFORM-MS, enrolled 48 patients across multiple U.S. sites. The company anticipates releasing topline data in late Q3 2026, with further presentation scheduled for the ACTRIMS and ECTRIMS meeting in October 2026.
Key Highlights
- Tiziana Life Sciences completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2a clinical trial.
- The trial evaluates intranasal foralumab for non-active Secondary Progressive Multiple Sclerosis (na-SPMS).
- Topline data from the INFORM-MS trial is expected in late Q3 of 2026.
- Data will be presented at the 10th joint ACTRIMS and ECTRIMS meeting in Toronto, Canada in October 2026.
- The multicenter study enrolled 48 patients across multiple U.S. sites.
- Patients will receive one of two doses of intranasal foralumab or placebo over a 12-week treatment period.
- An open-label extension phase will follow the blinded phase to assess long-term safety and benefit.
Price Impact
More from TLSA